Fanaptum: Withdrawal of the marketing authorisation application


Table of contents


On 13 March 2013, Vanda Pharmaceuticals Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Fanaptum for the treatment of schizophrenia.

Key facts

Product number
International non-proprietary name (INN) or common name
  • iloperidone
Active substance
  • iloperidone
Date of withdrawal
Company making the application
Vanda Pharmaceuticals Ltd
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating